A merger agreement between Shanghai Henlius Biotech (HKG:2696) and Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) has been terminated, a Wednesday Hong Kong bourse filing said.
Under the contract signed in June 2024, Fosun Pharma had agreed to acquire the shares it didn't already own in Henlius Biotech.
While the special resolution regarding the proposal was approved by the requisite majority at the firm's extraordinary general meeting, it was rejected at the H shareholders' class meeting.
Despite the deal falling through, Shanghai Fosun Pharmaceutical, which holds a 59.56% stake in Shanghai Henlius Biotech, will retain its controlling position in the latter.
Shares of Fosun Pharma were up over 1% in Hong Kong in recent trade, while Henlius Biotech fell over 4%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。